New York, October 06, 2015 -- Recent media and political scrutiny of US drug pricing will have only a minimal impact on the fundamental operating performance of the global pharmaceutical industry over the next 12-18 months, says Moody's Investors Service.
Vollständigen Artikel bei Moodys lesen